Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The study is a multi-center, prospective, one-arm, phase II clinical trial. It is tend to
examine the safety and efficacy of combining abraxane(albumin-bound paclitaxel） and
bevacizumab to treat patients with recurrent, platinum-resistant primary epithelial ovarian
cancer, fallopian tube cancer or peritoneal carcinoma.